David M. Nierengarten Recent News
Wedbush Cuts Fibrocell Science To Neutral
Wedbush On Anacor Pharma: Crisaborole Delivers, Reiterate Outperform
Bluebird Bio Shares Under Pressure As Wedbush Warns Of Pediatric Study Delay
Wedbush Initiates Blueprint Medicines At Outperform, Calls It A 'Template For Targeted Therapies'
Wedbush Sees More News On Bluebird Bio Coming Thursday
Wedbush Securities Reiterates Outperform, Raises PT On Medivation On Increased International Estimates
Wedbush Securities Sees Dose Escalation Trials Continue Without Toxicity Signals For Endocyte
Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma
Wedbush Previews Raptor Pharmaceutical Q4, Lowers Sales Estimates
UPDATE: Wedbush Reiterates On bluebird bio On Updated Data
UPDATE: Webush Initiates Coverage On Karyopharm Therapeutics Inc On Selinexor Potential
UPDATE: Wedbush Initiates Coverage on MEI Pharma as Best-in-Class Pracinostat Should Shine
UPDATE: Wedbush Initiates Coverage on Fate Therapeutics on Potential of Modified HSCs
UPDATE: Wedbush Downgrades Synageva BioPharma on Valuation
UPDATE: Wedbush Initiates Coverage on Stemline Therapeutics on Strong SL-401 Potential